Top research institutions, as well as many smaller research pharmacies across the country, are recognizing the value of our secure, web-based product to structure protocols in a logical way that lends itself to safety and compliance.
Ann Arbor, MI (PRWEB) February 24, 2015
McCreadie Group, Inc., a privately held pharmacy software company headquartered in Ann Arbor, Mich., announces Beth Israel Deaconess Medical Center (BIDMC) as a recent adopter of Vestigo®, the company’s web-based software for Investigational Drug Service (IDS) management.
By replacing manual processes, Vestigo adds efficiencies and accuracy to the workflow of investigational drug service operations. Vestigo supports the critical need for accountability in IDS and helps ensure that complex protocols are properly managed for consistency, safety and regulatory compliance.
Beth Israel Deaconess Medical Center (BIDMC) is one of the nation's most prominent academic medical centers and home to a distinguished academic research program. Each year, U.S. News & World Report ranks BIDMC as a "Best Hospital" in multiple specialties.
Attention was recently drawn to the principles and practices of IDS by the Hematology/Oncology Pharmacy Association (HOPA) Best Practice Standards, announced in September 2014. The standards are directed at organizations managing clinical research in cancer patients, but apply to any clinical research involving medications.
“Top research institutions, as well as many smaller research pharmacies across the country, are recognizing the value of our secure, web-based product to structure protocols in a logical way that lends itself to safety and compliance,” said Mike Schlesselman, PharmD, director of research products for McCreadie Group. “We are thrilled to have Beth Israel Deaconess join our growing list of esteemed clients.”
Launched in 2005, Vestigo is currently used by more than 50 percent of the 2014-2015 U.S. News & World Report top-ranked hospitals for cancer, 70 percent of the top NIH-funded research institutions and 40 percent of the NCI-designated cancer centers in the nation.
About McCreadie Group
The McCreadie Group, Inc. was founded in 2004 to provide software solutions for pharmacy applications in healthcare, research and educational settings. The company’s goal is to drive improvements in quality, efficiency, safety and compliance in the pharmacy profession by delivering innovative software and consultative support to healthcare providers, researchers and stakeholders in pharmacy education. To learn more about McCreadie Group and its products, visit http://www.mccreadiegroup.com.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Senior Life and is a research partner of Dana-Farber/Harvard Cancer Center and The Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.org.